Shirkadda British Biotechnology MiNA Therapeutics ‘innovative RNA therapy may enhance liver cancer patients’ response to standard treatment. The therapy uses a double-stranded RNA that can activate a target gene called CEBPA. Packaging double-stranded RNA in lipid nanoparticles helps to penetrate into liver cells that are often difficult to reach and can control gene expression in the nucleus. It is understood that the low level expression of certain genes is related to liver kansarka and other liver diseases. In laboratory studies, increasing the expression of CEBPA to restore its protein levels to normal can help reduce the growth of cancer cells.
Bukaannada qaata bayotechnoolajiyada yar yar ee firfircoon ee RNA (saRNA), laba ka mid ah ayaa muujiyay jawaab celin buuxda ka dib markii ay heleen sorafenib, kan kalena wuxuu muujiyay jawaab celin qayb ka dib daaweynta lenvatinib. Tani waa tijaabadii ugu horeysay ee daaweynta saRNA ee bini'aadamka. Maaddaama cilmi-baaristu ay weli ku jirto heerarkeedii hore, shirkadaha bayotechnoolajiyada hadda waxay rajeynayaan inay ururiyaan caddayn dheeraad ah oo ku habboon.
Shirkaddu waxay sidoo kale rajeyneysaa inay mustaqbalka ku sameyso tijaabo isku mid ah bukaanka qaba cirrhosis, waxayna sidoo kale iskaashi la sameysaa Boehringer Ingelheim si ay u fuliso mashaariicda kale ee cudurada beerka. Muddo dheer oo horumar ah ka dib, daawaynta RNA oo aad u badan ayaa soo gashay suuqa. Si ka duwan daawaynta MiNA ee dhaqaajisa muujinta hidda-wadaha, badi waxay adeegsadaan tignoolajiyada faragelinta RNA (RNAi) si ay u yareeyaan muujinta hidda-wadaha. Dhawaan, Guddiga Yurub waxay ansixiyeen Onpattro, daawadii ugu horreysay ee RNAi ee ay samaysay Alnylam ee daaweynta polyneuropathy.
